Demirtaş E, Sağ C, Kurşaklioğlu H, Uzun M, Uzbay T, Töre H F, Köse S, Genç C, Demirkan D
Faculty of Medicine, Department of Cardiology, Gülhane Military Medical Academy, Ankara, Turkey.
Jpn Heart J. 1998 Mar;39(2):173-81. doi: 10.1536/ihj.39.173.
Hypertrophic obstructive cardiomyopathy (HOCM), the cause of which is unknown, is a heart disease characterized by obstruction of the left ventricular outflow tract and an increase in interventricular septum thickness. Octreotide, a synthetic analogue of somatostatin, was administered subcutaneously to 15 patients for 6 months in order to determine its efficacy in HOCM. Echocardiographic examination was performed in each patient before we had initiated treatment and after treatment. Interventricular septum thickness, interventricular septum thickness/left ventricular posterior wall thickness, and subaortic gradient decreased significantly at the end of treatment. The ratio of the mitral valve E to A waves increased significantly. We observed that octreotide treatment caused a significant decrease in interventricular septum thickness and subaortic pressure gradient. Before and after therapy left ventricular enddiastolic diameter, left ventricular endsystolic diameter, ejection fraction and fractional shortening were not changed. No adverse effect was observed during the therapy. According to our results, octreotide has some beneficial effects on HOCM and it seems to be a new therapeutic approach for HOCM.
肥厚性梗阻性心肌病（HOCM）病因不明，是一种以左心室流出道梗阻和室间隔厚度增加为特征的心脏病。为了确定奥曲肽对HOCM的疗效，对15例患者皮下注射奥曲肽6个月。在开始治疗前和治疗后对每位患者进行超声心动图检查。治疗结束时，室间隔厚度、室间隔厚度/左心室后壁厚度和主动脉下梯度显著降低。二尖瓣E波与A波的比值显著增加。我们观察到奥曲肽治疗使室间隔厚度和主动脉下压力梯度显著降低。治疗前后左心室舒张末期直径、左心室收缩末期直径、射血分数和缩短分数没有变化。治疗期间未观察到不良反应。根据我们的结果，奥曲肽对HOCM有一些有益作用，似乎是治疗HOCM的一种新方法。
